Cannabics Pharmaceuticals Inc. (CNBX) Gains Foothold in Euro Cannabics Pharmaceuticals Inc. (CNBX) Gains Foothold in Europe
Cannabics Pharmaceuticals is an emerging pharmaceutical development company whose flagship product is Cannabics SR, a medical cannabis capsule specifically designed as a palliative care treatment for cancer patients. The company’s proprietary SR technology provides ten to twelve hours of steady-state, beneficial therapeutic effects and, consequently, allows for a convenient oral, once-per-day dosing regimen for patients.
Cannabics has been preparing to launch its line of SR products in eligible states of the US and EU markets under existing medical cannabis regulatory policies. The company is also now in its final stage of planning a series of formal clinical studies intended to demonstrate the unique medical benefits its products provide to patients suffering from various ailments.
In the first week of November 2014, Cannabics confirmed that it had executed an IP Licensing and Collaboration Agreement with Kalapa Holding, a leading medical cannabis provider and distributor in Spain, whose offerings include a diverse line of medical cannabinoid based products. The Cannabics-Kalapa agreement will guide the production and distribution of Cannabics SR products within the Spanish market.
In strict compliance with Spanish laws and regulations, Cannabics SR medical cannabis products will be available to certified patients only through a regulated Spanish entity and affiliate of Kalapa Holding, the Asociacion Centro Cannabico de Terapias Naturales. The products will be locally manufactured from pure extracts produced from high quality, organic medical cannabis strains by KSK Labs, another Kalapa Holding affiliate.
In collaborating with Kalapa Holding, Cannabics will unite the advanced cannabinoid administration technology implanted in its line of products with Kalapa’s operational capabilities and wide reach within the Spanish medical cannabis market. Management’s hope is that this synergy, which will allow Cannabics to offer its unique advanced products to European patients for the very first time, signals only the beginning of a long-lasting and successful partnership.
Cannabics Pharmaceuticals is focused on developing and marketing sophisticated drugs, therapies, food supplements and administration routes based on the active ingredients found in unique strains of the cannabis plant.
For more information, visit www.cannabics.com
Please see disclaimer on the QualityStocks website: https://Disclaimer.QualityStocks.com